Johnson & Johnson Criticized for Not Cooperating with Congressional Investigation

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Over the last eight months, Johnson & Johnson (NYSE: JNJ) has  recalled four popular over-the-counter products. The latest recall was announced in April for Tylenol, Motrin, Benadryl, and Zyrtec made for infants and children.

The US House Committee on Oversight and Government Reform has held hearings on the recalls, and the Food and Drug Administration is considering criminal charges or other actions against McNeil Consumer Healthcare, the J&J unit that manufactures the drugs. The FDA is investigating McNeil for its “patterns of violations in manufacturing and quality control practices that have led to a number of recent recalls,” according to The New York Times.

The House committee is steamed that J&J is stonewalling requests for information and that, in a few instances, has provided incorrect information. The company denies the charges, saying that it has responded in a timely fashion and has provided 20,000 pages of documents plus access to executives for interviews.

The committee chairman noted that J&J told the committee it had recalled 6 million bottles of children’s medicine, but it had told the FDA that it had recalled more than 136 million. The company’s explanation is that the 6 million figure represented the number of bottles on store shelves while the 136 million number was the estimate of  how many bottles are in the hands of consumers.

If any company should understand the value of a quick, clean, publicly acceptable course of action when confronted with a consumer threat, it’s J&J. Its handling of the 1982 tainted Tylenol cases is a textbook example of crisis communications.

But in case J&J simply forgot its history, it didn’t need to look back further than a week ago to get some guidance on how to behave. Faced with a PR disaster over glassware tainted with cadmium, McDonald’s Corp. (NYSE: MCD) immediately recalled the glasses and offered to pay purchasers $3 for each glass returned. The glasses cost $2 when they went on sale.

The McDonald’s glasses were a promotion for to get kids to drag their parents to McDonald’s for a meal and a cool glass. J&J’s recalled products were also aimed at kids.

If there’s one thing that unites every person in the US is a desire to protect kids from harm. McDonald’s knew the glasses it was selling were painted with cadmium, even though the amount used was not toxic and did not pose an acute risk to children. But the company also figured out that it’s not much of a leap for customers to associate unsafe glasses with unsafe food. How much would that cost McDonald’s? Rather than argue in the press, the company spent about $15 million to recall the glasses.

How much do you think J&J will spend trying to prove that it didn’t do anything wrong in making its drugs for kids or that it is fully cooperating with the FDA and the House investigations? It’s sure to be more than $15 million, and even if the company’s right, the loss of confidence in J&J could be far more costly.

Paul Ausick

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618